JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report

Mehrdad Payande1, Mohammad Erfan Zare1, 2, Saber Ghanbari Haji Shure2, Farhad Shaveisi Zadeh3

1Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran  
2Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran  
3Medical Genetics Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran

Corresponding Author: Mohammad Erfan Zare, BSC Student of Medical Lab Sciences  
Medical Biology Research Center, Sorkheh Lizheh, Kermanshah University of Medical Sciences, Kermanshah, Iran  
P.O.Box: 1568  
Tel: +98 831 4276473  
Fax: +98 831 4276471  
E-mail: mezarelab@yahoo.com

Abstract
Myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, primary myelofibrosis and chronic myeloid leukemia have too similar and accurate way to differentiate their is study of genetic disorders in these patients. Philadelphia chromosome is a sure way to definitively diagnose CML. Recently, JAK2V617F mutation introduced as a diagnostic marker for other Myeloproliferative neoplasms. Many studies show that the absence of the JAK2 mutation in chronic phase Philadelphia positive CML. In contrast with these reports, more recently, several cases with the coexistence of Philadelphia positive chromosome and JAK2V617F mutation in blood and bone marrow samples were reported. Here, we report a patient that have the Philadelphia chromosome disorder and JAK2V617F mutation in same time.

Keyword: Myeloproliferative neoplasms, chronic myeloid leukemia, JAK2V617F, JAK2

Introduction
Myeloproliferative neoplasms (MPNs) which include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PM) and chronic myeloid leukemia (CML) have almost similar clinical and laboratory features and most accurate way to differentiate them is detect genetic disorders in these patients.(1-3) Detection of the Philadelphia chromosome in CML patients, causing a massive change in the diagnosis of this malignancy and differentiation that from other neoplasms. However, detection of common genetic disorders in other classic myeloproliferative neoplasms had long-term issue for scientist’s research. Finally in 2005, common JAK2V617F mutation was detected by different research groups.(4-8) JAK2 is a tyrosine kinase that has an important role in the signalling pathways of many haemopoietic growthfactor receptors. The single acquired point mutation V617F (1849G>T) in JAK2 occurs in 50–97% of patients with idiopathic myelofibrosis, essential thrombocythemia, and polycythemia vera.(4-6, 8, 9) By contrast, the JAK2V617F mutation has never been identified in a patient with Philadelphia positive CML.(10) But recently, some cases of Philadelphia positive CML with concomitant JAK2V617F mutation have been reported.(11-18) Here, we report a patient that have the Philadelphia chromosome disorder and JAK2V617F mutation in same time.

Case presentation
In February 2011 the 82-year-old male patient with leukocytosis, thrombocytosis, anemia and LDH level higher than normal (763U/L) was referred to us. Hematological parameters at presentation were as follows: White Blood Cells (WBC) 20×10^9/L, Hemoglobin 8.3 g/dL and platelets 958×10^9/L. Physical examination were normal with no palpable spleen enlargement. A bone marrow biopsy revealed marked hypercellularity (90%) composed of polymorphic population of hematopoietic cells and also Megakaryocytes are increased in number. The clinical symptom of the patient was suspected
ET and treatment with Hydroxyurea (HU) was started. For diagnosis, Philadelphia chromosomal disorder and JAK2V617F mutation testing was performed. Expression of B2A2 BCR-ABL mRNA (chimer protein 210 KD) was detected by a reverse transcriptase polymerase chain reaction (RT-PCR) in peripheral blood leucocytes.

We performed the JAK2 mutation test to detect this mutation on genomic DNA (ARMS-PCR) and RNA (ASO-PCR) which had been isolated from the whole peripheral blood of the patient. A diagnosis of BCR-ABL positive chronic myeloid leukaemia (CML) was made and treatment with hydroxyurea continued with the goal of lowering blood cell count. After 2 weeks, the platelet count returned to normal but white blood cell count had increased. But, the patient was suffering from severe anemia (Haemoglobin 7.7 g/dL) and we changed his drug by imatinib. The patient showed allergy to this drug and suffered severe muscle spasms and bone pain and we changed his drug by Interferon α again. The last laboratory test after 4 months of initial diagnosis showed decrease levels of LDH. Hematological parameters at this test were as follows: White Blood Cells (WBC) 19.7×10⁹/L, Haemoglobin 10 g/dL and platelets 375×10⁹/L.

**ARMS PCR for the detection of JAK2-V617F mutations:** Genomic DNA was extracted by phenol/chloroform after proteinase K digestion, following standard techniques. The JAK2 V617F mutation was detected by ARMS-PCR with some modification.

The ARMS-PCR technique uses 4 primers as follows; a forward outer primer, a reverse outer primer, a forward inner wild type specific primer and a reverse inner mutant specific primer. The forward primer from one set and the reverse from the other generate a control 463-bp band in all cases. The reverse inner mutant specific primer and the forward outer primer generate a 279-bp mutant fragment. In the presence of the wild-type JAK2, the reverse outer primer and the forward inner wildtype specific primer produce a fragment of 229-bp. PCR reaction was performed within a total volume of 25 µL containing approximately 25 ng DNA, 12.5 µL of TaqMan Universal PCR Master Mix 2X (Roche, Germany), 0.5 µL of each FO, RO and Fwt, and 1µL of Rmt primer.

The PCR program on the thermal cycler (Eppendorf) was as follows: an initial denaturation step at 94°C for 6 min, followed by 40 cycles of 40 sec. at 94°C, 45 sec. at 56°C, 45 sec. at 72°C, and a final extension step of 10 min at 72°C.(19)

**Table- 1. ARMS PCR primers (MWG Biotech, Germany)**

<table>
<thead>
<tr>
<th>Type</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forward Outer (FO)</td>
<td>5’- TCC TCA GAA CGT TGA TGG CAG - 3’</td>
</tr>
<tr>
<td>Reverse Outer (RO)</td>
<td>5’- ATT GCT TTFCCTT TTT CAC AAG AT - 3’</td>
</tr>
<tr>
<td>Forward wild-type specific (Fwt)</td>
<td>5’- GCATTGTT TTAAATTAGGAGTTATG - 3’</td>
</tr>
<tr>
<td>Reverse mutant-specific (Rmt)</td>
<td>5’- GTT TTA CTT ACT CTC GTC TCC ACA AAA - 3’</td>
</tr>
</tbody>
</table>

**Table- 2. ASO PCR primers (MWG Biotech, Germany)**

<table>
<thead>
<tr>
<th>Type</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forward</td>
<td>5’- GAA GAT TTG ATA TTT AAT GAA AGC CTT - 3’</td>
</tr>
<tr>
<td>Reverse</td>
<td>5’- GTA ATA CTA ATG CCA GGA TCA CTA AGT T - 3’</td>
</tr>
<tr>
<td>Mutant</td>
<td>5’- AGC ATT TGG TTT TAA ATT ATG GAG TAT ATT - 3’</td>
</tr>
</tbody>
</table>

**ASO- PCR for the detection of the JAK2-V617F mutation:** Total RNAs were isolated by using the TRIZOL reagent. First, strand cDNAs were prepared by reverse transcription of total RNAs with random primers. The ASO- PCR program was as follows: an initial denaturation step at 95°C for 5 min, followed by 40 cycles of 40 sec. at 94°C, 40 sec. at 56°C, 45 sec. at 72°C, and a final extension step of 10 min at 72°C. The mutant specific forward amplified a 295-bp product from the mutated allele, whereas the internal control forward primer should have given a 488-bp product from both the mutant and wild-type alleles (Figure- 2). A total of 10 µl from the PCR product were electrophoresed on 3% standard agarose gels (Sigma, Germany) at 80 V for 15 min. The fragments were visualized by ethidium bromide under UV transilluminator.(19)

**Discussion**

Recently, a number of reports have described the coexistence of the JAK2V617F mutation in patients with Philadelphia positive CML.(11-18) There is a debate as to whether MPD and CML arise separately from each other, representing independent development from a normal stem cell, or whether the Philadelphia chromosome arises in a stem cell of a MPD clone.(16) In some cases, the mutated JAK2 was detected after therapy for CML with imatinib or other agents but retrospective analyses of the initial specimen in those cases demonstrated that the mutated JAK2 was present at the time of the initial diagnosis of CML.(13, 15- 16) Campiotti et al. have prospectively detected JAK2 mutation positivity in one patient among 13 new cases of Philadelphia positive CML. After the partial cytogenetic response to imatinib treatment, JAK2 mutation was disappeared. Therefore, they have firstly hypothesized that imatinib treatment...
have caused the regression of CML clone, as well as JAK2 mutated cells, and that JAK2 mutation can be acquired by Philadelphia positive cells. (18) But in most cases, as described previously, imatinib mesylate therapy did not affect the coexisting and/or acquired JAK2 clone. (12-17) In addition, a number of cases of CML have been reported in patients with well-established polycythemia vera, primary myelofibrosis, or ET with mutated JAK2. (11, 20-23) The patient described in this study before refer to us, had not any hematologic disorder. Likely, it can be concluded that he has the Philadelphia chromosome and JAK2 mutated in the same time. Although some authors have postulated that the BCR-ABL1 fusion gene and the abnormal JAK2 occur in independent cell populations, (15) most evidence indicates that they occur simultaneously in the same cells and that the JAK2V617F mutation likely precedes the BCRABL1 abnormality. (11)

**Conclusion**

Even though the JAK2V617F mutation has been excluded in a large cohort of BCR-ABL patients; (10) the present report gives evidence that the coexistence of these two disease-specific mutations is possible. This is still a question that whether MPN and CML arise separately from each other, representing independent development from a normal stem cell, or whether the Philadelphia chromosome arises in a stem cell of a MPN clone. Further studies are required to determine the exact frequency and prognostic role of the JAK2V617F mutation in Philadelphia positive CML patients.

**References**